0000000000451013

AUTHOR

Fabrizio Calapai

showing 5 related works from this author

Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence

2017

Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal.

gamma-hydroxybutyrateGHB; alcohol abstinence.; alcohol withdrawal; gamma-hydroxybutyrate; gamma-hydroxybutyric acid; sodium oxybateSettore MED/43 - Medicina Legalealcohol abstinence.alcohol withdrawalgamma-hydroxybutyric acidSettore BIO/14 - FarmacologiaGHBsodium oxybate
researchProduct

Neurological aspects of medical use of cannabidiol

2017

Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. Objective: The aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, t…

0301 basic medicinemedicine.medical_specialtyNeurologyCannabidiol; Neurodegenerative diseases; Neurological; Neurology; Neuroprotection; Neuroscience (all); PharmacologyDiseaseBioinformaticsNeurodegenerative diseaseNeuroprotection03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleCentral Nervous System DiseasesMedicineAnimalsCannabidiolHumansneurodegenerative diseasesYoung adultAmyotrophic lateral sclerosisPharmacologyNeuroscience (all)biologybusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseasebiology.organism_classificationNeuroprotection030104 developmental biologyNeuroprotective AgentsNeurologyNeurologicalcannabidiol; neurodegenerative diseases; neurological; neurology; neuroprotectionCannabisbusinessCannabidiol030217 neurology & neurosurgerymedicine.drug
researchProduct

Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence

2018

BACKGROUND Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal. OBJECTIVE The aim of the present review was to describe the state of art of the pre-clinical research and the clinical evidence related to GHB used alone or in combination with other treatments in alcohol withdrawal syndrome and alcohol abstinence maintenance. METHOD Internationally published pre-clinical findings and clinical studi…

medicine.medical_specialtySodium Oxybatemedia_common.quotation_subjectClinical Biochemistry01 natural sciencesNaltrexone03 medical and health sciences0302 clinical medicinemedicineHumansmedia_common.cataloged_instance030216 legal & forensic medicineEuropean unionPsychiatrymedia_commonPharmacologyAlcohol Abstinencebusiness.industry010401 analytical chemistryGamma hydroxybutyrategamma-Hydroxybutyric acidAbstinencemedicine.diseaseSubstance Withdrawal Syndrome0104 chemical sciencesAlcohol withdrawal syndromeSodium OxybatebusinessAlcohol-Related DisordersCentral Nervous System AgentsAlcohol Abstinencemedicine.drugCurrent Drug Metabolism
researchProduct

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

2021

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. With the increasing spectrum of therapeutic options, it is th…

safetyPolypharmacydrug-drug interactionsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInflammatory bowel disease elderly patients safety drug-drug interactionsGastroenterologyDiseaseelderly patientsmedicine.diseaseInflammatory bowel diseaseUlcerative colitisInflammatory bowel diseaseVedolizumabClinical trialUstekinumabInternal MedicinemedicineAdverse effectIntensive care medicinebusinessmedicine.drugMinerva Gastroenterology
researchProduct

Clinical pharmacology of citrus aurantium and citrus sinensis for the treatment of anxiety

2018

Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects ofCitrus aurantiumorCitrus sinensisessential oils (EOs).Design. The bibliographic research was made on the major scientific databases. Analysis included only articles written in English and published on peer-reviewed scientific journals describing preclinical experiments and clinical trials carried out to investigate the antianxiety effects ofCitrus aurantium or Citrus sinensisEOs on anxiety disorders. Clinical studies reporting the antianxiety effects of products containingCitrus aurantiumorCitrus sinensisEOs in combination with other active substances, including medicinal pla…

medicine.drug_classAnxietyAnxiolyticlaw.invention03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegalelawmedicineCitrus aurantium; Citrus sinensis; Anxiety; Complementary and Alternative Medicine030212 general & internal medicineMedicinal plantsCitrus aurantiumClinical pharmacologyTraditional medicinebusiness.industryPharmacology Citrus aurantium Citrus sinensis Anxietyfood and beverageslcsh:Other systems of medicinelcsh:RZ201-999Clinical trialComplementary and alternative medicineAnxiogenicAnxietymedicine.symptombusiness030217 neurology & neurosurgeryCitrus × sinensisCitrus sinensisAromatherapy
researchProduct